Contrast enhanced ultrasound ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
96	Crohn disease	3

96. Crohn disease

---

Clinical trials : 2,442 /  Drugs : 1,278 - (DrugBank : 248) / Drug target genes : 142 - Drug target pathways : 209

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04660136 (ClinicalTrials.gov)	December 1, 2020	2/12/2020	Usefulness of Contrast-enhanced Ultrasound (CEUS) in Crohn's Disease Pediatric Patients	Usefulness of Contrast-enhanced Ultrasound (CEUS) in Crohn's Disease Pediatric Patients	Crohn's Disease in Pediatric Patient	Biological: contrast enhanced ultrasound	Yonsei University	NULL	Recruiting	2 Years	18 Years	All	20	Phase 4	Korea, Republic of
2	NCT02061163 (ClinicalTrials.gov)	February 2015	6/2/2014	Contrast-Enhanced Ultrasound in Human Crohn's Disease	Evaluation of Contrast-Enhanced Ultrasound in Human Crohn's Disease	Crohn's Disease	Device: Contrast Enhanced Ultrasound;Drug: Optison	University of Michigan	NULL	Withdrawn	10 Years	N/A	Both	0	Phase 1/Phase 2	United States
3	EUCTR2015-002882-41-AT (EUCTR)		05/11/2015	A Pilot Study on the use of contrast enhanced ultrasound in Crohn’s disease	Sono-­Response-­StudyA Pilot Study on the use of contrast enhanced ultrasound in Crohn’s disease	Inflammatory bowel disease (Crohn's disease) MedDRA version: 18.1;Level: PT;Classification code 10011401;Term: Crohn's disease;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Trade Name: SonoVue Product Name: SonoVue INN or Proposed INN: sulphur hexafluoride Other descriptive name: SULFUR HEXAFLUORIDE	Medical University of Vienna (MUW)	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Austria